MicroQuin Ltd is a pioneering biotech company based in Cambridge, MA, revolutionizing disease treatment by controlling the intracellular environment (ICE). Their innovative approach focuses on developing first-in-class therapeutics, with a particular emphasis on cancer, anti-virals, and neuro treatments, supported by renowned institutions and collaborators.
MicroQuin's pipeline includes their lead small molecule, SMQ-2174, an orally available drug that induces rapid cancer death across various cancer types, aiming to transform cancer treatment for solid tumors. With a recent grant from the Department of Defense Congressionally Directed Medical Research Programs (DoD CDMRP) for ovarian cancer treatment development, MicroQuin is at the forefront of advancing medical solutions to combat diseases.
Generated from the website